tiprankstipranks
Merck & Company (GB:0QAH)
LSE:0QAH
UK Market
0QAH
Merck & Company
RESEARCH TOOLSreports

Merck & Company (0QAH) Share Forecast & Price Target

6 Followers
See the Price Targets and Ratings of:

0QAH Analyst Ratings

Moderate Buy
18Ratings
Moderate Buy
13 Buy
5 Hold
0 Sell
Based on 18 analysts giving stock ratings to
Merck
& Company
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0QAH Stock 12 Month Forecast

Average Price Target

$158.09
▲(7.10% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is $158.09 with a high forecast of $180.00 and a low forecast of $105.00. The average price target represents a 7.10% change from the last price of $147.61.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"80":"$80","181":"$181","105.25":"$105.3","130.5":"$130.5","155.75":"$155.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":158.08705882352942,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$158.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$105.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[80,105.25,130.5,155.75,181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,149.136,151.51015384615386,153.8843076923077,156.25846153846155,158.63261538461538,161.00676923076924,163.38092307692307,165.75507692307693,168.12923076923076,170.50338461538462,172.87753846153845,175.2516923076923,177.62584615384614,{"y":180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,149.136,149.82454298642534,150.5130859728507,151.201628959276,151.89017194570135,152.5787149321267,153.26725791855205,153.95580090497737,154.6443438914027,155.33288687782806,156.0214298642534,156.70997285067872,157.39851583710407,{"y":158.08705882352942,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,149.136,145.74092307692308,142.34584615384614,138.95076923076923,135.5556923076923,132.16061538461537,128.76553846153845,125.37046153846154,121.97538461538461,118.58030769230768,115.18523076923077,111.79015384615384,108.39507692307691,{"y":105,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":81.068,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.175,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.198,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.152,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.156,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.845,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.872,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.11,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.878,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.946,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.96,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.136,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$180.00Average Price Target$158.09Lowest Price Target$105.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on GB:0QAH
Daina Graybosch
Leerink Partners
Leerink Partners
$127→$161
Buy
9.07%
Upside
Reiterated
09/09/26
Merck price target raised to $161 from $127 at LeerinkMerck price target raised to $161 from $127 at Leerink
Guggenheim Analyst forecast on GB:0QAH
Vamil Divan
Guggenheim
Guggenheim
$146→$170
Buy
15.17%
Upside
Reiterated
09/08/26
Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NASDAQ: NAMS), Merck & Company (NYSE: MRK) and Royalty Pharma (NASDAQ: RPRX)
Bernstein Analyst forecast on GB:0QAH
Courtney Breen
Bernstein
Bernstein
$105
Hold
-28.87%
Downside
Reiterated
09/07/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Intellia Therapeutics (NASDAQ: NTLA) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
Barclays Analyst forecast on GB:0QAH
Emily Field
Barclays
Barclays
$162.85→$174.48
Hold
18.20%
Upside
Reiterated
09/07/26
Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Merck & Company (NYSE: MRK)
Wells Fargo Analyst forecast on GB:0QAH
Mohit Bansal
Wells Fargo
Wells Fargo
$150→$170
Buy
15.17%
Upside
Assigned
09/04/26
Merck price target raised to $170 from $150 at Wells FargoMerck price target raised to $170 from $150 at Wells Fargo
Scotiabank Analyst forecast on GB:0QAH
Louise Chen
Scotiabank
Scotiabank
$155
Buy
5.01%
Upside
Reiterated
08/31/26
Scotiabank Reaffirms Their Buy Rating on Merck & Company (MRK)
RBC Capital Analyst forecast on GB:0QAH
Trung Huynh
RBC Capital
RBC Capital
$150
Hold
1.62%
Upside
Reiterated
08/25/26
RBC Capital Reaffirms Their Hold Rating on Merck & Company (MRK)
Wolfe Research Analyst forecast on GB:0QAH
Alexandria Hammond
Wolfe Research
Wolfe Research
$155→$180
Buy
21.94%
Upside
Reiterated
08/25/26
Merck price target raised to $180 from $155 at Wolfe ResearchMerck price target raised to $180 from $155 at Wolfe Research
Argus Research Analyst forecast on GB:0QAH
Jasper Hellweg
Argus Research
Argus Research
$145→$170
Buy
15.17%
Upside
Reiterated
08/24/26
Merck price target raised to $170 from $145 at ArgusMerck price target raised to $170 from $145 at Argus
BMO Capital Analyst forecast on GB:0QAH
Evan Seigerman
BMO Capital
BMO Capital
$142→$170
Buy
15.17%
Upside
Reiterated
08/20/26
BMO Capital Sticks to Their Buy Rating for Merck & Company (MRK)
Goldman Sachs Analyst forecast on GB:0QAH
Asad Haider
Goldman Sachs
Goldman Sachs
$140→$160
Buy
8.39%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Moderna (NASDAQ: MRNA) and Akari Therapeutics (NASDAQ: AKTX)
UBS Analyst forecast on GB:0QAH
Michael Yee
UBS
UBS
$145→$175
Buy
18.56%
Upside
Reiterated
08/20/26
Merck price target raised to $175 from $145 at UBSMerck price target raised to $175 from $145 at UBS
Bank of America Securities Analyst forecast on GB:0QAH
Jason Gerberry
Bank of America Securities
Bank of America Securities
$141→$166
Buy
12.46%
Upside
Reiterated
08/19/26
Merck price target raised to $166 from $141 at BofAMerck price target raised to $166 from $141 at BofA
Morgan Stanley Analyst forecast on GB:0QAH
Terence Flynn
Morgan Stanley
Morgan Stanley
$116→$179
Buy
21.27%
Upside
Upgraded
08/19/26
Merck upgraded to Overweight from Equal Weight at Morgan StanleyMerck upgraded to Overweight from Equal Weight at Morgan Stanley
J.P. Morgan Analyst forecast on GB:0QAH
Chris Schott
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
08/19/26
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Moderna (NASDAQ: MRNA) and Merck & Company (NYSE: MRK)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on GB:0QAH
Daina Graybosch
Leerink Partners
Leerink Partners
$127→$161
Buy
9.07%
Upside
Reiterated
09/09/26
Merck price target raised to $161 from $127 at LeerinkMerck price target raised to $161 from $127 at Leerink
Guggenheim Analyst forecast on GB:0QAH
Vamil Divan
Guggenheim
Guggenheim
$146→$170
Buy
15.17%
Upside
Reiterated
09/08/26
Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NASDAQ: NAMS), Merck & Company (NYSE: MRK) and Royalty Pharma (NASDAQ: RPRX)
Bernstein Analyst forecast on GB:0QAH
Courtney Breen
Bernstein
Bernstein
$105
Hold
-28.87%
Downside
Reiterated
09/07/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Intellia Therapeutics (NASDAQ: NTLA) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
Barclays Analyst forecast on GB:0QAH
Emily Field
Barclays
Barclays
$162.85→$174.48
Hold
18.20%
Upside
Reiterated
09/07/26
Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Merck & Company (NYSE: MRK)
Wells Fargo Analyst forecast on GB:0QAH
Mohit Bansal
Wells Fargo
Wells Fargo
$150→$170
Buy
15.17%
Upside
Assigned
09/04/26
Merck price target raised to $170 from $150 at Wells FargoMerck price target raised to $170 from $150 at Wells Fargo
Scotiabank Analyst forecast on GB:0QAH
Louise Chen
Scotiabank
Scotiabank
$155
Buy
5.01%
Upside
Reiterated
08/31/26
Scotiabank Reaffirms Their Buy Rating on Merck & Company (MRK)
RBC Capital Analyst forecast on GB:0QAH
Trung Huynh
RBC Capital
RBC Capital
$150
Hold
1.62%
Upside
Reiterated
08/25/26
RBC Capital Reaffirms Their Hold Rating on Merck & Company (MRK)
Wolfe Research Analyst forecast on GB:0QAH
Alexandria Hammond
Wolfe Research
Wolfe Research
$155→$180
Buy
21.94%
Upside
Reiterated
08/25/26
Merck price target raised to $180 from $155 at Wolfe ResearchMerck price target raised to $180 from $155 at Wolfe Research
Argus Research Analyst forecast on GB:0QAH
Jasper Hellweg
Argus Research
Argus Research
$145→$170
Buy
15.17%
Upside
Reiterated
08/24/26
Merck price target raised to $170 from $145 at ArgusMerck price target raised to $170 from $145 at Argus
BMO Capital Analyst forecast on GB:0QAH
Evan Seigerman
BMO Capital
BMO Capital
$142→$170
Buy
15.17%
Upside
Reiterated
08/20/26
BMO Capital Sticks to Their Buy Rating for Merck & Company (MRK)
Goldman Sachs Analyst forecast on GB:0QAH
Asad Haider
Goldman Sachs
Goldman Sachs
$140→$160
Buy
8.39%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Moderna (NASDAQ: MRNA) and Akari Therapeutics (NASDAQ: AKTX)
UBS Analyst forecast on GB:0QAH
Michael Yee
UBS
UBS
$145→$175
Buy
18.56%
Upside
Reiterated
08/20/26
Merck price target raised to $175 from $145 at UBSMerck price target raised to $175 from $145 at UBS
Bank of America Securities Analyst forecast on GB:0QAH
Jason Gerberry
Bank of America Securities
Bank of America Securities
$141→$166
Buy
12.46%
Upside
Reiterated
08/19/26
Merck price target raised to $166 from $141 at BofAMerck price target raised to $166 from $141 at BofA
Morgan Stanley Analyst forecast on GB:0QAH
Terence Flynn
Morgan Stanley
Morgan Stanley
$116→$179
Buy
21.27%
Upside
Upgraded
08/19/26
Merck upgraded to Overweight from Equal Weight at Morgan StanleyMerck upgraded to Overweight from Equal Weight at Morgan Stanley
J.P. Morgan Analyst forecast on GB:0QAH
Chris Schott
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
08/19/26
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Moderna (NASDAQ: MRNA) and Merck & Company (NYSE: MRK)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ARDXArdelyx
ZVRAZevra Therapeutics
HROWHarrow Health
KURAKura Oncology
SNDXSyndax Pharmaceuticals
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

3 Months
Asad HaiderGoldman Sachs
Success Rate
12/13 ratings generated profit
92%
Average Return
+11.97%
Copying Asad Haider's trades and holding each position for 3 Months would result in 92.31% of your transactions generating a profit, with an average return of +11.97% per trade.
1 Year
Asad HaiderGoldman Sachs
Success Rate
13/13 ratings generated profit
100%
Average Return
+42.13%
Copying Asad Haider's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +42.13% per trade.
2 Years
Asad HaiderGoldman Sachs
Success Rate
13/13 ratings generated profit
100%
Average Return
+51.01%
Copying Asad Haider's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +51.01% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QAH Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
1
1
0
0
0
Buy
49
43
44
52
43
Hold
18
18
16
16
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
68
62
60
68
54
In the current month, 0QAH has received 43 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. 0QAH average Analyst price target in the past 3 months is 158.09.
Each month's total comprises the sum of three months' worth of ratings.

0QAH Financial Forecast

0QAH Earnings Forecast

Next quarter’s earnings estimate for 0QAH is $2.22 with a range of $2.01 to $2.41. The previous quarter’s EPS was -$0.13. 0QAH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0QAH has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0QAH is $2.22 with a range of $2.01 to $2.41. The previous quarter’s EPS was -$0.13. 0QAH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0QAH has Performed in-line its overall industry.

0QAH Sales Forecast

Next quarter’s sales forecast for 0QAH is $17.32B with a range of $16.75B to $17.84B. The previous quarter’s sales results were $16.58B. 0QAH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0QAH has Performed in-line its overall industry.
Next quarter’s sales forecast for 0QAH is $17.32B with a range of $16.75B to $17.84B. The previous quarter’s sales results were $16.58B. 0QAH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0QAH has Performed in-line its overall industry.

0QAH Stock Forecast FAQ

What is GB:0QAH’s average 12-month price target, according to analysts?
Based on analyst ratings, Merck & Company’s 12-month average price target is 158.09.
    What is GB:0QAH’s upside potential, based on the analysts’ average price target?
    Merck & Company has 7.10% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Merck & Company a Buy, Sell or Hold?
          Merck & Company has a consensus rating of Moderate Buy, which is based on 13 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Merck & Company’s share price target?
            The average share price target for Merck & Company is 158.09. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $180.00 ,and the lowest forecast is $105.00. The average share price target represents 7.10% Increase from the current price of $147.61.
              What do analysts say about Merck & Company?
              Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of Merck & Company?
                To buy shares of GB:0QAH, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.